# Combination Chemotherapy and Denileukin Diftitox in Treating Patients With Newly Diagnosed T-Cell Non-Hodgkin Lymphoma

> **NCT00513188** · NA · WITHDRAWN · sponsor: **University of Miami**

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** denileukin diftitox
- **DRUG:** cyclophosphamide
- **DRUG:** cytarabine
- **DRUG:** doxorubicin hydrochloride
- **DRUG:** leucovorin calcium
- **DRUG:** methotrexate
- **DRUG:** prednisone
- **DRUG:** vincristine sulfate
- **GENETIC:** protein expression analysis
- **OTHER:** flow cytometry
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00513188
- **Lead sponsor:** University of Miami
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2007-02
- **Primary completion:** 2008-06
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2016-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00513188

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00513188, "Combination Chemotherapy and Denileukin Diftitox in Treating Patients With Newly Diagnosed T-Cell Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00513188. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*